Pratley RE, Kang J, Trautmann ME, et al. - In adults without diabetes, researchers conducted this phase II, randomized, placebo-controlled, double-blind trial to assess the safety of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, and its impacts on body weight management. For this investigation, candidates with a BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidity were randomized 1:1:1:1:1 to efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 week, or 8 mg once every 2 week; n = 237) or placebo (n = 60) in combination with a hypocaloric diet. According to findings, efpeglenatide was well tolerated once a week and once every 2 weeks, and treatment was linked with a substantial and clinically meaningful decrease in body weight in individuals who were obese or overweight (with comorbidity) without diabetes. Improvements in glycaemic and lipid variables were correlated with the weight loss impacts, consistent with an overall metabolism advantage. These results promote further development in obese individuals of efpeglenatide. The most common treatment-emergent adverse events were the gastrointestinal effects.